LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

Search

DexCom Inc

Chiusa

SettoreSettore sanitario

69.73 1.19

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

68.85

Massimo

71.01

Metriche Chiave

By Trading Economics

Entrata

-68M

200M

Vendite

-68M

1.2B

P/E

Media del settore

29.644

50.958

EPS

0.56

Margine di Profitto

16.738

Dipendenti

11,000

EBITDA

-52M

337M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+19.86% upside

Dividendi

By Acuity

Utili prossimi

29 lug 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

3B

27B

Apertura precedente

68.54

Chiusura precedente

69.73

Notizie sul Sentiment di mercato

By Acuity

18%

82%

35 / 342 Classifica in Healthcare

DexCom Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Chi Siamo DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
help-icon Live chat